abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Sells $588,549.22 in Stock

Posted by Danessa Lincoln on Sep 24th, 2025

abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 41,623 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $14.14, for a total transaction of $588,549.22. Following the sale, the insider owned 2,837,633 shares in the company, valued at approximately $40,124,130.62. The trade was a 1.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Friday, September 19th, Saba Capital Management, L.P. sold 6,989 shares of abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.10, for a total transaction of $98,544.90.
On Thursday, September 18th, Saba Capital Management, L.P. sold 40,208 shares of abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.07, for a total transaction of $565,726.56.
On Wednesday, September 17th, Saba Capital Management, L.P. sold 24,328 shares of abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.99, for a total transaction of $340,348.72.
On Tuesday, September 16th, Saba Capital Management, L.P. sold 2,026 shares of abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.99, for a total transaction of $28,343.74.
On Monday, September 15th, Saba Capital Management, L.P. sold 700 shares of abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.13, for a total transaction of $9,891.00.
On Thursday, September 11th, Saba Capital Management, L.P. sold 15,116 shares of abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.28, for a total transaction of $215,856.48.
On Tuesday, September 2nd, Saba Capital Management, L.P. sold 14,083 shares of abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.04, for a total transaction of $197,725.32.
On Friday, August 29th, Saba Capital Management, L.P. sold 23,723 shares of abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.89, for a total transaction of $329,512.47.
On Tuesday, August 26th, Saba Capital Management, L.P. sold 400 shares of abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.83, for a total transaction of $5,532.00.
On Thursday, August 21st, Saba Capital Management, L.P. sold 10,710 shares of abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.07, for a total transaction of $150,689.70.

abrdn Life Sciences Investors Stock Down 0.1%

Shares of HQL opened at $14.11 on Wednesday. abrdn Life Sciences Investors has a 1 year low of $10.55 and a 1 year high of $15.60. The company has a 50 day simple moving average of $13.69 and a two-hundred day simple moving average of $12.92.

abrdn Life Sciences Investors Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Friday, August 22nd will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 11.9%. The ex-dividend date of this dividend is Friday, August 22nd.

Institutional Investors Weigh In On abrdn Life Sciences Investors

A number of institutional investors have recently added to or reduced their stakes in HQL. Geneos Wealth Management Inc. grew its holdings in abrdn Life Sciences Investors by 200.1% during the 2nd quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock valued at $29,000 after buying an additional 1,529 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new position in shares of abrdn Life Sciences Investors in the first quarter valued at $131,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of abrdn Life Sciences Investors in the first quarter valued at $134,000. Wedbush Securities Inc. purchased a new position in shares of abrdn Life Sciences Investors in the first quarter valued at $149,000. Finally, Stratos Wealth Partners LTD. grew its holdings in shares of abrdn Life Sciences Investors by 7.4% in the first quarter. Stratos Wealth Partners LTD. now owns 14,176 shares of the company’s stock valued at $180,000 after purchasing an additional 971 shares in the last quarter. 32.21% of the stock is owned by hedge funds and other institutional investors.

abrdn Life Sciences Investors Company Profile

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.